Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and long-term safety of dupilumab plus topical corticosteroids in adults with moderate-to-severe atopic dermatitis
2013-003254-24Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Dupilumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoint: EASI-75 response at week 16. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2013-003254-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003254-24.